Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances
- CMHC
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
$0.00
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors.
- CMHC
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
The coexistence of type 2 diabetes and chronic kidney disease significantly exacerbates cardiovascular and renal morbidity and mortality compared to either condition alone. Even with the advent of newer therapies in patients with T2D and CKD, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, residual morbidity, and mortality remain, and additional strategies to slow kidney disease progression, particularly to address inflammation and fibrosis as a contributing factor to CKD progression, are needed.
- CMHC
- 1.50 AAFP
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
$0.00
This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, and emerging insulin options. The information is presented in an interactive format, which contains a mix of high-impact visuals, infographics, expert faculty videos, as well as resources and suggested readings, all organized into different segments to facilitate learning.
- CMHC
- TME
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
$0.00
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras).
- CMHC
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDE
- 1.50 Participation
$0.00
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events. Despite advancements in LDL-C lowering therapies, achieving LDL-C targets remains suboptimal due to clinical inertia and patient non-adherence, contributing to patient's residual ASCVD risk. The landscape of LDL-C lowering therapies is rapidly evolving, with several new and emerging agents that may help bridge these gaps.
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
- CMHC
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDE
- 1.50 Participation
$0.00
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enhance CVD risk prediction in certain patients. As emerging CVD risk factors, including Lp(a), are increasingly recognized as a target for therapy in the prevention and treatment of ASCVD, clinicians should be aware of the therapeutic advances in this field.
- CMHC
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
$0.00
Effectively managing high cholesterol level and safely lowering LDL-C is crucial for preventing and reducing the risk of adverse cardiovascular events. However, achieving LDL-C goals remains suboptimal, particularly in high-risk and very high-risk patients. The landscape of lipid lowering therapy has significantly evolved, with new consensus statements, newer agents, and important evidence that may help address some current gaps.
- CMHC
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 CDE
- 0.50 Participation
$0.00
This Ace the Case Series is designed to be quick and offer high-level takeaways and pearls.Case #1: A 37-Year-Old Man with Incidental Hepatic Steatosis on Abdominal UltrasoundDuring this Ace the Case activity, you will learn about risk factors for metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), and advanced fibrosis, as well as the current and emerging noninvasive liver assessment tests.
- CMHC
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
$0.00
This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA. The session, "The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes" was presented by Debbie Cohen, MDDr. Cohen discussed:
- CMHC
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA. The symposium, "The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes" was presented by Pam R. Taub, MD, Erin D. Michos, MD, and Jennifer Green, MD.